In this study, we report a case of a SMARCA4‐deficient undifferentiated urothelial carcinoma that was effectively treated with nivolumab (Nivo; anti‐programmed cell death protein [PD‐1] blockade) after early relapse following treatment for non‐invasive bladder cancer. This evidence concerns the gene SMARCA4 and urinary bladder cancer.